Vollständiger Abstract
Worum geht es in dieser Arbeit?
Abstract In this phase II trial, patients with endometrial cancer (EC) were randomized to everolimus/letrozole with (experimental arm) or without ribociclib (control arm) (ClinicalTrials.gov Identifier: NCT03008408). The primary endpoint was progression-free survival (PFS). Secondary endpoints included toxicity, overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR). For all-comers, there was no difference in PFS (HR 0.78, 95% CI 0.4-1.4, p = 0.38), OS (HR 0.8, 95% CI 0.4-1.5, p = 0.46), ORR (44.1% vs 25.7%, p = 0.11), or toxicity-related treatment discontinuation (4 [8.6%] vs 3 [11.4%], p = 0.22). Among those with prior endocrine therapy, ORR was higher in the experimental arm (61.5% vs 0.0%, p < 0.001). Within the experimental arm, CTNNB1 mut tumors were associated with improved PFS (HR 0.27, 95% CI 0.1-0.7, p = 0.006) and OS (HR 0.24, 95% CI 0.1-0.7, p = 0.004) compared to those with non- CTNNB1 mut tumors. Despite no survival improvement in all-comers, addition of ribociclib to everolimus/letrozole may improve efficacy in patients with prior endocrine therapy and cases with CTNNB1 mut tumors may have prolonged response.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Jeffrey A. How, Shannon N. Westin, Melissa Pham, Barrett Lawson, Minxing Chen, Nidhi Tandon, Ying Yuan, Rugang Zhang, Amir A. Jazaeri, Anil K. Sood, Michaela Onstad Grinsfelder, Kathleen M. Schmeler, David J. Vining, Samantha M. Fix, Yibo Dai, Mikayla B. Bowen, Karen H. Lu, Melinda S. Yates, Russell Broaddus, Pamela T. Soliman
- Quelle
- Nature Communications
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 2041-1723
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Jeffrey A. How, Shannon N. Westin, Melissa Pham, Barrett Lawson, Minxing Chen, Nidhi Tandon, Ying Yuan, Rugang Zhang, Amir A. Jazaeri, Anil K. Sood, Michaela Onstad Grinsfelder, Kathleen M. Schmeler, David J. Vining, Samantha M. Fix, Yibo Dai, Mikayla B. Bowen, Karen H. Lu, Melinda S. Yates, Russell Broaddus, Pamela T. Soliman (2026). Efficacy of everolimus and letrozole with or without ribociclib in recurrent endometrial cancer: a phase 2 randomized clinical trial. Nature Communications. https://doi.org/10.1038/s41467-026-77049-3
Kontext
Themen, Förderung und Nutzung
Lizenzhinweise: Lizenz 1